Reuters logo
BRIEF-Takeda presents updated results from pivotal phase 2 ALTA trial of ALUNBRIGTM
2017年10月16日 / 早上7点51分 / 1 个月前

BRIEF-Takeda presents updated results from pivotal phase 2 ALTA trial of ALUNBRIGTM

Oct 16 (Reuters) - Takeda Pharmaceutical Co Ltd:

* Takeda presents updated results from pivotal phase 2 ALTA trial of ALUNBRIGTM (brigatinib) in alk-positive non-small cell lung cancer

* Takeda Pharmaceutical Co Ltd says ‍confirmed objective response rate, which was primary endpoint, was 46 percent in arm a and 55 percent in arm b​

* Takeda pharmaceutical co ltd says ‍efficacy and safety data from alta trial continue to support future trials with 180 mg dosing regimen​

* Takeda pharmaceutical co ltd says ‍median overall survival os was not reached in arm a and 27.6 months in arm b​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below